{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:56:23Z","timestamp":1790898983858,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Xiamen Healthcare Guidance Project","award":["no. 3502Z20244ZD1115"],"award-info":[{"award-number":["no. 3502Z20244ZD1115"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["no. 2025J011499"],"award-info":[{"award-number":["no. 2025J011499"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16471-8","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:15:27Z","timestamp":1783174527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["LAR\/NMLR stratify mortality risk before and after checkpoint inhibitor pneumonitis in NSCLC: multi-state and time-dependent analyses"],"prefix":"10.1186","volume":"26","author":[{"given":"Qingwei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9735-4408","authenticated-orcid":false,"given":"Yuting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"20","key":"16471_CR1","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"22","key":"16471_CR2","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"19","key":"16471_CR3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"6","key":"16471_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(6):586\u201397.","journal-title":"J Clin Oncol"},{"issue":"36","key":"16471_CR5","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"7","key":"16471_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1\/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017;35(7):709\u201317.","journal-title":"J Clin Oncol"},{"issue":"7","key":"16471_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1164\/rccm.201803-0525RR","volume":"198","author":"R Sternschein","year":"2018","unstructured":"Sternschein R, Moll M, Ng J, D\u2019Ambrosio C. Immune Checkpoint Inhibitor-related Pneumonitis. Incidence, Risk Factors, and Clinical and Radiographic Features. Am J Respir Crit Care Med. 2018;198(7):951\u20133.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"16471_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338.","journal-title":"Ann Oncol"},{"issue":"12","key":"16471_CR9","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"4","key":"16471_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492\u20139.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"16471_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","volume":"14","author":"K Suresh","year":"2019","unstructured":"Suresh K, Psoter KJ, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, et al. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. J Thorac Oncol. 2019;14(3):494\u2013502.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"16471_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(3):351\u20137.","journal-title":"JAMA Oncol"},{"issue":"10","key":"16471_CR13","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaoncol.2019.1747","volume":"5","author":"D Kazandjian","year":"2019","unstructured":"Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer. JAMA Oncol. 2019;5(10):1481\u20135.","journal-title":"JAMA Oncol"},{"key":"16471_CR14","doi-asserted-by":"publisher","first-page":"698832","DOI":"10.3389\/fonc.2021.698832","volume":"11","author":"X Lin","year":"2021","unstructured":"Lin X, Deng H, Yang Y, Wu J, Qiu G, Li S, Xie X, Liu M, Xie Z, Qin Y, et al. Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer. Front Oncol. 2021;11:698832.","journal-title":"Front Oncol"},{"key":"16471_CR15","doi-asserted-by":"publisher","first-page":"1473962","DOI":"10.3389\/fimmu.2025.1473962","volume":"16","author":"M Luo","year":"2025","unstructured":"Luo M, Wei H, Qiu M, Su C, Ning R, Zhou S. Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy. Front Immunol. 2025;16:1473962.","journal-title":"Front Immunol"},{"issue":"5","key":"16471_CR16","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.21037\/tcr-2024-2577","volume":"14","author":"B Wei","year":"2025","unstructured":"Wei B, Cui H, Qian K, Shi K, Zhang P, Zhang Y. Prognostic value of lactate dehydrogenase to albumin ratio in first-line chemoimmunotherapy for locally advanced or metastatic non-small cell lung cancer. Transl Cancer Res. 2025;14(5):2956\u201365.","journal-title":"Transl Cancer Res"},{"issue":"6","key":"16471_CR17","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.21037\/tlcr-21-156","volume":"10","author":"A Sanchez-Gastaldo","year":"2021","unstructured":"Sanchez-Gastaldo A, Munoz-Fuentes MA, Molina-Pinelo S, Alonso-Garcia M, Boyero L, Bernabe-Caro R. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab. Transl Lung Cancer Res. 2021;10(6):2509\u201322.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"16471_CR18","doi-asserted-by":"publisher","first-page":"967","DOI":"10.21037\/tlcr.2020.04.14","volume":"9","author":"M Aldea","year":"2020","unstructured":"Aldea M, Benitez JC, Mezquita L. The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients. Transl Lung Cancer Res. 2020;9(4):967\u201370.","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"16471_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"16471_CR20","unstructured":"SERVICES USDOHAH. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017:Available at: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"16471_CR21","doi-asserted-by":"publisher","first-page":"110837","DOI":"10.1016\/j.radonc.2025.110837","volume":"207","author":"D Ruysscher","year":"2025","unstructured":"Ruysscher D, Wauters E, Jendrossek V, Filippi AR, Revel MP, Faivre-Finn C, Naidoo J, Ramella S, Guckenberger M, Ricardi U, et al. Diagnosis and treatment of radiation induced pneumonitis in patients with lung cancer: An ESTRO clinical practice guideline. Radiother Oncol. 2025;207:110837.","journal-title":"Radiother Oncol"},{"key":"16471_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","volume":"125","author":"JY Cho","year":"2018","unstructured":"Cho JY, Kim J, Lee JS, Kim YJ, Kim SH, Lee YJ, Cho YJ, Yoon HI, Lee JH, Lee CT, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer. 2018;125:150\u20136.","journal-title":"Lung Cancer"},{"issue":"2","key":"16471_CR23","doi-asserted-by":"publisher","first-page":"104329","DOI":"10.1016\/j.lpm.2025.104329","volume":"55","author":"C Mahiat","year":"2025","unstructured":"Mahiat C, Cadranel J, Fallet V, Meteye C, Gendarme S, Slomka J, Canellas A. Pulmonary toxicity of immune-checkpoint inhibitors. Presse Med. 2025;55(2):104329.","journal-title":"Presse Med"},{"issue":"8","key":"16471_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cllc.2023.08.014","volume":"24","author":"M Petranovic","year":"2023","unstructured":"Petranovic M, McDermott S, Mercaldo S, Little BP, Graur A, Huang K, Fintelmann FJ, Digumarthy SR, Gainor JF. Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2023;24(8):682\u2013e688685.","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"16471_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1159\/000543556","volume":"103","author":"L Cui","year":"2025","unstructured":"Cui L, Cheng K, Cui M, Li X. Characteristics and Risk Factors of Immune Checkpoint Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer: A Retrospective Study. Oncology. 2025;103(8):699\u2013708.","journal-title":"Oncology"},{"issue":"12","key":"16471_CR26","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.annonc.2020.09.016","volume":"31","author":"N Shaverdian","year":"2020","unstructured":"Shaverdian N, Beattie J, Thor M, Offin M, Shepherd AF, Gelblum DY, Wu AJ, Simone CB 2nd, Hellmann MD, Chaft JE, et al. Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors. Ann Oncol. 2020;31(12):1719\u201324.","journal-title":"Ann Oncol"},{"issue":"2","key":"16471_CR27","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.chest.2021.02.032","volume":"160","author":"WT Atchley","year":"2021","unstructured":"Atchley WT, Alvarez C, Saxena-Beem S, Schwartz TA, Ishizawar RC, Patel KP, Rivera MP. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina. Chest. 2021;160(2):731\u201342.","journal-title":"Chest"},{"issue":"5 Suppl","key":"16471_CR28","first-page":"86","volume":"27","author":"S Menekse","year":"2023","unstructured":"Menekse S, Almuradova EKE. Elevated serum lactate dehydrogenase to albumin ratio is a useful poor prognostic predictor of nivolumab in patients with non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2023;27(5 Suppl):86\u201394.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"16471_CR29","doi-asserted-by":"publisher","first-page":"100254","DOI":"10.1016\/j.esmoop.2021.100254","volume":"6","author":"G Mountzios","year":"2021","unstructured":"Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open. 2021;6(5):100254.","journal-title":"ESMO Open"},{"key":"16471_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.lungcan.2018.08.012","volume":"124","author":"K Sekine","year":"2018","unstructured":"Sekine K, Kanda S, Goto Y, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Ohe Y. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer. 2018;124:179\u201388.","journal-title":"Lung Cancer"},{"issue":"1","key":"16471_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41698-022-00262-y","volume":"6","author":"T Rajakumar","year":"2022","unstructured":"Rajakumar T, Horos R, Jehn J, Schenz J, Muley T, Pelea O, Hofmann S, Kittner P, Kahraman M, Heuvelman M, et al. A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy. NPJ Precis Oncol. 2022;6(1):19.","journal-title":"NPJ Precis Oncol"},{"key":"16471_CR32","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","volume":"340","author":"LE Levesque","year":"2010","unstructured":"Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.","journal-title":"BMJ"},{"issue":"11","key":"16471_CR33","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389\u2013430.","journal-title":"Stat Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16471-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16471-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16471-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:52:11Z","timestamp":1790898731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16471-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16471"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16471-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol of this retrospective study was approved by the Ethics Committee of Zhongshan Hospital (Xiamen), Fudan University (ZSXMEC) (No. B2025-058). Informed consent was waived as the research involved no more than minimal risk and the use of de-identified archival data. The study was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1175"}}